Comprehensive mapping of somatotroph pituitary neuroendocrine tumour heterogeneity using spatial and single-cell transcriptomics

Abstract

	•The first-ever visualization of cellular distributions in normal and tumor pituitary tissues.
	•The inter-and intra-tumoral transcriptomic heterogeneity of somatotroph PitNETs was comprehensively revealed.
	•Identification of potential protumor factors and critical signaling pathways, opening new avenues for therapeutic intervention.

Keywords

somatotroph PitNETs / spatial transcriptomics / single-cell RNA sequencing / tumour heterogeneity

References

[1] Ben-Shlomo A, Deng N, Ding E, et al. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. J Clin Invest. 2020;130(11):5738-5755.

[2] Zhang F, Zhang Q, Zhu J, et al. Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumours. Cell Res. 2022;32(12):1047-1067.

[3] Kober P, Rymuza J, Baluszek S, et al. DNA methylation pattern in somatotroph pituitary neuroendocrine tumours. Neuroendocrinology. 2024;114(1):51-63.

[4] Yamato A, Nagano H, Gao Y, et al. Proteogenomic landscape and clinical characterization of gh-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumours. Commun Biol. 2022;5(1):1304.

[5] Colao A, Grasso LFS, Giustina A, et al. Acromegaly. Nat Rev Dis Primers. 2019;5(1):20.

[6] Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2011;32(2):247-271.

[7] Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10(11):804-826.

[8] Zhang Q, Yao B, Long X, et al. Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of pitnet. Cell Rep Med. 2023;4(2):100934.

[9] Wu L, Yan J, Bai Y, et al. An invasive zone in human liver cancer identified by stereo-seq promotes hepatocyte-tumour cell crosstalk, local immunosuppression and tumour progression. Cell Res. 2023;33(8):585-603.

[10] Zhang XB, Lian PH, Su MM, et al. Single-cell transcriptome analysis identifies a unique tumour cell type producing multiple hormones in ectopic acth and crh secreting pheochromocytoma. eLife. 2021;10:e68436.

[11] Asuzu DT, Alvarez R, Fletcher PA, et al. Pituitary adenomas evade apoptosis via noxa deregulation in Cushing’s disease. Cell Rep. 2022;40(8):111223.

[12] Zhang D, Hugo W, Bergsneider M, et al. Single-cell rna sequencing in silent corticotroph tumours confirms impaired pomc processing and provides new insights into their invasive behavior. Eur J Endocrinol. 2022;187(1):49-64.

[13] Yan N, Xie W, Wang D, et al. Single-cell transcriptomic analysis reveals tumour cell heterogeneity and immune microenvironment features of pituitary neuroendocrine tumours. Genome Med. 2024;16(1):2.

[14] Cui Y, Li C, Jiang Z, et al. Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumours. Neuro Oncol. 2021;23(11):1859-1871.

[15] Lyu L, Jiang Y, Ma W, et al. Single-cell sequencing of pit1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by ifn-gamma-induced tumour-associated fibroblasts remodelling. Br J Cancer. 2023;128(6):1117-1133.

[16] Arora R, Cao C, Kumar M, et al. Spatial transcriptomics reveals distinct and conserved tumour core and edge architectures that predict survival and targeted therapy response. Nat Commun. 2023;14(1):5029.

[17] Wang F, Long J, Li L, et al. Single-cell and spatial transcriptome analysis reveals the cellular heterogeneity of liver metastatic colorectal cancer. Sci Adv. 2023;9(24):eadf5464.

[18] Oyoshi H, Du JY, Sakai SA, et al. Comprehensive single-cell analysis demonstrates radiotherapy-induced infiltration of macrophages expressing immunosuppressive genes into tumour in esophageal squamous cell carcinoma. Sci Adv. 2023;9(50):eadh9069.

[19] Peng L, Jin X, Li B-Y, et al. Integrating single-cell rna sequencing with spatial transcriptomics reveals immune landscape for interstitial cystitis. Signal Transduct Target Ther. 2022;7(1).

[20] Qi J, Sun H, Zhang Y, et al. Single-cell and spatial analysis reveal interaction of fap+ fibroblasts and spp1+ macrophages in colorectal cancer. Nat Commun. 2022;13(1).

[21] Bassiouni R, Idowu MO, Gibbs LD, et al. Spatial transcriptomic analysis of a diverse patient cohort reveals a conserved architecture in triple-negative breast cancer. Cancer Res. 2023;83(1):34-48.

[22] Thrane K, Eriksson H, Maaskola J, Hansson J, Lundeberg J. Spatially resolved transcriptomics enables dissection of genetic heterogeneity in stage iii cutaneous malignant melanoma. Cancer Res. 2018;78(20):5970-5979.

[23] Berglund E, Maaskola J, Schultz N, et al. Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity. Nat Commun. 2018;9(1):2419.

[24] Li X, Wang CY. From bulk, single-cell to spatial rna sequencing. Int J Oral Sci. 2021;13(1):36.

[25] Melmed S, Kaiser UB, Lopes MB, et al. Clinical biology of the pituitary adenoma. Endocr Rev. 2022;43(6):1003-1037.

[26] Zhang S, Cui Y, Ma X, et al. Single-cell transcriptomics identifies divergent developmental lineage trajectories during human pituitary development. Nat Commun. 2020;11(1):5275.

[27] Gao CF, Vande Woude GF. Hgf/sf-met signalling in tumour progression. Cell Res. 2005;15(1):49-51.

[28] Vimalraj S. A concise review of vegf, pdgf, fgf, notch, angiopoietin, and hgf signalling in tumour angiogenesis with a focus on alternative approaches and future directions. Int J Biol Macromol. 2022;221:1428-1438.

[29] Wang MH, Zhou XM, Zhang MY, et al. Bmp2 promotes proliferation and invasion of nasopharyngeal carcinoma cells via mtorc1 pathway. Aging. 2017;9(4):1326-1340.

[30] Fukuda T, Fukuda R, Tanabe R, et al. Bmp signalling is a therapeutic target in ovarian cancer. Cell Death Discov. 2020;6(1):139.

[31] Wang Y, Sakaguchi M, Sabit H, et al. Col1a2 inhibition suppresses glioblastoma cell proliferation and invasion. J Neurosurg. 2023;138(3):639-648.

[32] Huo X, Ma S, Wang C, et al. Unravelling the role of immune cells and fn1 in the recurrence and therapeutic process of skull base chordoma. Clin Transl Med. 2023;13(10).

[33] Kim M-C, Borcherding N, Ahmed KK, et al. Cd177 modulates the function and homeostasis of tumour-infiltrating regulatory T cells. Nat Commun. 2021;12(1).

[34] Chhabra Y, Weeraratna AT. Fibroblasts in cancer: unity in heterogeneity. Cell. 2023;186(8):1580-1609.

[35] Lin L, Lin DC. Biological significance of tumour heterogeneity in esophageal squamous cell carcinoma. Cancers. 2019;11(8):1156.

[36] Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the rosetta stone of therapy resistance. Cancer Cell. 2020;37(4):471-484.

[37] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.

[38] Marques P, Korbonits M. Tumour microenvironment and pituitary tumour behaviour. J Endocrinol Invest. 2023;46(6):1047-1063.

[39] Marques P, Barry S, Carlsen E, et al. Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness. Endocr Relat Cancer. 2019;26(12):853-865.

[40] Jiang Q, Lei Z, Wang Z, et al. Tumor-associated fibroblast-derived exosomal circdennd1b promotes pituitary adenoma progression by modulating the mir-145-5p/onecut2 axis and activating the mapk pathway. Cancers. 2023;15(13):3375.

[41] Song ZJ, Reitman ZJ, Ma ZY, et al. The genome-wide mutational landscape of pituitary adenomas. Cell Res. 2016;26(11):1255-1259.

[42] Bi WL, Horowitz P, Greenwald NF, et al. Landscape of genomic alterations in pituitary adenomas. Clin Cancer Res. 2017;23(7):1841-1851.

[43] Pittaway JFH, Lipsos C, Mariniello K, Guasti L. The role of delta-like non-canonical notch ligand 1 (dlk1) in cancer. Endocr Relat Cancer. 2021;28(12):R271-R287.

[44] Yin D, Xie D, Sakajiri S, et al. Dlk1: increased expression in gliomas and associated with oncogenic activities. Oncogene. 2006;25(13):1852-1861.

[45] Takagi H, Zhao S, Muto S, et al. Delta-like 1 homolog (dlk1) as a possible therapeutic target and its application to radioimmunotherapy using 125i-labelled anti-dlk1 antibody in lung cancer models (hot1801 and fight004). Lung Cancer. 2021;153:134-142.

[46] Huang C-C, Cheng S-H, Wu C-H, et al. Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of notch signalling. Oncogene. 2019;38(17):3201-3215.

[47] Zhou Y, Li L, Tan J, et al. Dlk1 promotes lung cancer cell invasion through upregulation of mmp9 expression depending on notch signalling. PLoS One. 2014;9(3).

[48] Fleseriu M, Biller BMK, Freda PU, et al. A pituitary society update to acromegaly management guidelines. Pituitary. 2020;24(1):1-13.

[49] Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 who classification of pituitary tumours. Endocr Pathol. 2022;33(1):6-26.

[50] Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33(5):495-502.

[51] Stuart T, Butler A, Hoffman P, et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888-1902. e1821.

[52] Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573-3587. e3529.

[53] Cillo AR, Kürten CHL, Tabib T, et al. Immune landscape of viral-and carcinogen-driven head and neck cancer. Immunity. 2020;52(1):183-199. e189.

[54] Yu G, Wang L-G, Han Y, He Q-Y. Clusterprofiler: an r package for comparing biological themes among gene clusters. Omics. 2012;16(5):284-287.

[55] Hänzelmann S, Castelo R, Guinney J. Gsva: gene set variation analysis for microarray and rna-seq data. BMC Bioinf. 2013;14:7.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.